CLINICAL TRIALS PROFILE FOR ERYTHROCIN
✉ Email this page to a colleague
All Clinical Trials for ERYTHROCIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02381080 ↗ | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | Janssen Research & Development, LLC | Phase 1 | 2015-05-19 | The purpose of this study is to assess the effect of a moderate Cytochrome P450 (CYP) 3A inhibitor (erythromycin) and a strong CYP3A inhibitor (voriconazole) on the steady-state pharmacokinetics (PK [the study of the way a drug enters and leaves the blood and tissues over time]) of repeated oral doses of ibrutinib in participants with B-cell malignancy (cancer or other progressively enlarging and spreading tumors). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ERYTHROCIN
Condition Name
Clinical Trial Locations for ERYTHROCIN
Clinical Trial Progress for ERYTHROCIN
Clinical Trial Phase
Clinical Trial Sponsors for ERYTHROCIN
Sponsor Name